Chiron Investment Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Chiron Investment Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,891	Closed	-$234K	–	103
2023 Q2	$234K	Buy	1,891 +1,661	+722%	+$223K	0.07%	99
2023 Q1	$33.7K	Sell	230 -1,790	-89%	-$265K	0.01%	126
2022 Q4	$322K	Buy	+2,020	New	+$296K	0.08%	69
2021 Q3	–	Sell	-136,817	Closed	-$24.3M	–	114
2021 Q2	$24.3M	Buy	+136,817	New	+$23.7M	2.93%	11
2020 Q4	$14.5M	Buy	87,783 +2,430	+3%	+$362K	2.01%	17
2020 Q3	$12.2M	Buy	+85,353	New	+$10.6M	2.26%	14
2020 Q2	–	Sell	-2,400	Closed	-$239K	–	81
2020 Q1	$239K	Buy	+2,400	New	+$310K	0.06%	42
2019 Q1	–	Sell	-1,219	Closed	-$151K	–	61
2018 Q4	$151K	Buy	1,219 +200	+20%	+$29.7K	0.02%	45
2018 Q3	$171K	Sell	1,019 -653	-39%	-$112K	0.01%	55
2018 Q2	$288K	Buy	+1,672	New	+$273K	0.02%	42

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Chiron Investment Management's JAZZ Position: Q3 2023 in Review

Chiron Investment Management sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2023, closing a stake of 1,891 shares — an estimated $234K sold.

Chiron Investment Management first reported a position in JAZZ in Q2 2018 and held it in 10 quarters. The position peaked at $24.3M in Q2 2021. 484 funds tracked by Wall St. Rank hold JAZZ as of Q3 2023.

Chiron Investment Management reported no remaining Jazz Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Chiron Investment Management sold 1,891 Jazz Pharmaceuticals shares in Q3 2023, an estimated $234K.
Chiron Investment Management first reported a position in Jazz Pharmaceuticals in Q2 2018 and held it in 10 quarters.
Chiron Investment Management's Jazz Pharmaceuticals position peaked at $24.3M in Q2 2021.
484 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2023.

Based on Chiron Investment Management's 13F filing for Q3 2023, filed 13 Nov 2023.